Unusual 11 Mid-Day Movers 9/27: (GI) (DRRX) (KTOV) Higher; (CVM) (CZR) (AOI) Lower

September 27, 2016 12:55 PM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

EndoChoice Holdings, Inc. (NYSE: GI) 89.3% HIGHER; Boston Scientific and EndoChoice Holdings announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire EndoChoice. Upon completion of the transaction, EndoChoice will become part of the Boston Scientific endoscopy business.

CEL-SCI Corporation (NYSE: CVM) 37.5% LOWER; announced that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold.

DURECT Corporation (Nasdaq: DRRX) 20.7% HIGHER; rebounding from earlier in the week after announcing that its licensee, Pain Therapeutics (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Pain Therapeutics' New Drug Application (NDA) for REMOXY® ER (oxycodone) extended-release capsules CII. Based on its review, the FDA has determined that the NDA cannot be approved in its present form and specifies additional actions and data that are needed for drug approval.

Kitov Pharmaceuticals Holdings Ltd. (Nasdaq: KTOV) 20.7% HIGHER; announced that its lead drug candidate KIT-302 has successfully completed an additional pharmacokinetic (PK) bioequivalence (BE) study and once more successfully met the U.S. Food and Drug Administration's (FDA) standards for establishing bioequivalence to the reference drugs. The current study evaluated a lower dosage (2.5 mg) of amlodipine than in Kitov's previous PK bioequivalence study for the KIT-302 product containing 10 mg of amlodipine, the results of which were announced by Kitov on May 10, 2016.

Caesars Entertainment Corporation (Nasdaq: CZR) 15.5% LOWER; Caesars Entertainment and Caesars Entertainment Operating Company, Inc. ("CEOC") and its Chapter 11 debtor subsidiaries today announced that they have received confirmation from representatives of CEOC's major creditor groups of those groups' support for a term sheet that describes the key economic terms of a proposed consensual chapter 11 plan for the Debtors.

Alliance One International, Inc. (NYSE: AOI) 14.0% LOWER; announced its intention to offer, subject to market and other conditions, $275 million in aggregate principal amount of its senior secured first lien notes due April 15, 2021 (the "Notes") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act") and to persons in offshore transactions in reliance on Regulation S under the Securities Act.

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) 13.0% LOWER; initiated a Phase 2 clinical trial of Actimab-A in patients newly diagnosed with Acute Myeloid Leukemia (AML) who are over the age of 60. Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program consists of the CD33 targeting monoclonal antibody, HuM195, and the alpha-emitting radioisotope, actinium-225.

Vanguard Natural Resources (Nasdaq: VNR) 12.3% LOWER; Hilliard Lyons downgraded Vanguard Natural Resources from Long-Term Buy to Neutral and removed its price target (prior $12.00).

Juno Therapeutics (Nasdaq: JUNO) 11.1% HIGHER; higher on news from peer Kite Pharma.

SYNNEX Corp. (NYSE: SNX) 8.7% HIGHER; reported Q3 EPS of $1.73, $0.17 better than the analyst estimate of $1.56. Revenue for the quarter came in at $3.67 billion versus the consensus estimate of $3.49 billion. SYNNEX Corp. sees Q4 2016 EPS of $2.06-$2.11, versus the consensus of $1.93. SYNNEX Corp. sees Q4 2016 revenue of $3.83-.93 billion, versus the consensus of $3.77 billion.

Kite Pharma, Inc., (Nasdaq: KITE) 8.7% HIGHER; announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19, in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL). KTE-C19 met the primary endpoint of objective response rate (ORR), p<0.0001, with ORR of 76 percent, including 47 percent complete remissions (CR).

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Hilliard Lyons, Unusual 11 Mid-Day Movers, Bankruptcy, Vanguard, Definitive Agreement

Add Your Comment